Даваа–Баасан 08:30–20:00 · Бямба 09:00–16:00
Now showing 1 - 3 of 3
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Association Between IL-28B Polymorphism and Clinical Laboratory Features in Patients with Chronic Hepatitis D
    (Mongolian National University of Medical Sciences, 2017-11-25)
    Bayarsaikhan, Uyanga
    ;
    ; ;
    Objectives: We aimed to determine an association between IL-28B rs12989760 single nucleotide polymorphism (SNP) and clinical laboratory parameters in patients with chronic hepatitis D. Methods: A total of 59 patients who were chronically infected with HDV were had their serum tested for the presence of qHBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc, anti-HCV, anti-HDV IgM, anti-HDV IgG, HDV RNA, HBV DNA and AFP. Liver function tests, coagulation tests and CBC were also performed. IL-28B polymorphism was performed using a TaqMan 5' allelic discrimination assay by real time PCR. Results: Of these 59 patients, 40 patients (67.8 %) carried the rs12979860CC homozygote genotype, 11 patients (18.6%) were rs12979860CC homozygote and 8 patients (13.6%) were rs12979860CT heterozygote. Alkaline phosphatase and direct bilirubin values were higher (p<0.05) and total protein levels were lower (p<0.05) in patients who were homozygotes for the T allele as opposed to the carriers of the C allele. AFP levels were significantly higher (p=0.02) in the rs12979860 TT genotype group. Liver enzymes including AST, ALT and GGT were significantly not higher in patients who carry C allele (p>.05). Conclusion: The most frequent genotype was IL-28B rs12979860CC among patients with chronic hepatitis D. The IL-28B rs12979860 polymorphism was associated with some abnormal liver function test parameters and AFP levels. Additional studies are necessary to understand the immune mechanisms of IL-28B polymorphism in HDV infection.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Prevalence of major noncommunicable diseases and risk factors by region: Findings from the National Screening
    (Mongolian National University of Medical Sciences, 2025-12-26) ;
    Enkh-Amgalan, Enkhtuguldur
    ;
    ; ;
    Objective: Noncommunicable diseases (NCDs) are the leading causes of morbidity and mortality worldwide, accounting for the majority of premature deaths. Mongolia faces a particularly high burden of cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes, contributing to over 80% of total deaths. This study aimed to examine the prevalence of major NCDs and associated risk factors among the adult population of Mongolia by region. Methods: This study utilized large-scale screening data from the mass screening program of adults aged over 18 years. Results: A total of 447,409 adults were included in the analyses. High prevalence of NCD risk factors was observed, including smoking (16.6-19.1%), alcohol use (5.9-11.7%), physical inactivity (76%–80%), and insufficient fruit and vegetable intake (63%–79%). Regional comparison showed that the Northern region had the highest rates of smoking (19.2%), alcohol use (13.4%), and obesity (24.7%) (p<0.001). In contrast, Ulaanbaatar reported notably higher rates of chronic gastritis and peptic ulcer disease (82.2%–18.5%) compared to other rural regions (p<0.001). Conclusion: NCD risk factors are common across all regions of Mongolia, with clear differences between them. Notably, the urban population has higher rates of stomach and esophageal inflammation and ulcers, likely linked to lifestyle factors and obesity.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    One-year antibody kinetics and effectiveness of a BNT162b2 booster after four primary COVID-19 vaccination regimens in Mongolia
    (2026-09)
    Bazarjav, Purevbat
    ;
    Erdene-Ochir, Tseyenkhorloo
    ;
    Sandagdorj, Ankhbayar
    ;
    Enkhtuvshin, Altansukh
    ;
    Enkhbayar, Purevjargal
    BACKGROUND: Waning immunity after primary COVID-19 vaccination and the widespread use of heterogeneous vaccine platforms have created uncertainty regarding the durability of protection following booster vaccination. Mongolia implemented a mixed-platform vaccination program and deployed BNT162b2 as a booster. We evaluated the immunogenicity, effectiveness, and safety of a BNT162b2 booster following four primary vaccination regimens with 12 months follow-up. METHODS: In this prospective observational study in Ulaanbaatar, Mongolia, adults (≥18 years) who had completed a homologous two-dose primary series with BBIBP-CorV, ChAdOx1 nCoV-19, Gam-COVID-Vac, or BNT162b2 received a BNT162b2 booster a median of 189 days (IQR 186-215) after the second dose and were grouped according to their primary vaccination regimen. Humoral immune responses (anti-SARS-CoV-2 N/S1-RBD IgG, S-RBD IgG, and neutralizing antibodies) were measured at baseline and at multiple time points up to 12 months after booster vaccination. Reactogenicity was monitored for 28 days. SARS-CoV-2 infection was ascertained by a positive antigen/lateral-flow test and/or RT-PCR. VE was estimated for prespecified follow-up intervals by comparing the risk of SARS-CoV-2 infection in each boosted group with that in an unvaccinated comparison group. FINDINGS: Among 311 participants (mean age 41.88 years [SD 13.64]; 175 [56.27%] women and 136 [43.73%] men), antibody responses peaked at day 14 and declined through day 365 in all groups. At day 14, total antibody concentrations were highest in BNT + BNT (385.03 U/mL) and lowest in Gam + BNT (341.74 U/mL). S-RBD IgG at day 14 was highest in BNT + BNT (967.0 ng/mL) and lowest in BBIBP+BNT (863.70 ng/mL). Neutralizing antibodies at day 14 were highest in BNT + BNT (368.13 AU/mL) and BBIBP+BNT (336.70 AU/mL). During follow-up, 64 participants acquired SARS-CoV-2 infection and 15 (23.44%) were admitted to hospital. Reactogenicity was predominantly mild-to-moderate, and laboratory parameters were generally within acceptable ranges. Vaccine effectiveness declined from 1 month to 12 months: BBIBP+BNT 90.54% (95% CI 59.71-97.78) to 71.17% (39.66-86.23); ChAd+BNT 84.97% (49.75-95.51) to 52.59% (8.61-75.41); Gam + BNT 89.68% (23.95-98.60) to 63.84% (15.10-84.60); BNT + BNT 91.89% (40.06-98.90) to 72.29% (34.37-88.30). INTERPRETATION: A BNT162b2 booster following diverse primary COVID-19 vaccination regimens induced strong humoral responses that declined over 12 months and showed an acceptable reactogenicity profile. VE against SARS-CoV-2 infection was highest soon after boosting and lower later in follow-up. Although antibody levels and VE showed similar temporal patterns, these findings should be interpreted as complementary outcomes rather than evidence of a direct causal relationship or a formal immunological correlate of protection.